Bioverativ Inc. (BIVV) Tops Q4 Views

Bioverativ Inc. (NASDAQ: BIVV) reported Q4 EPS of $1.30, which may not compare to the analyst estimate of $0.89. Revenue for the quarter came in at $328.7 million versus the consensus estimate of $326.58 million.

“We are proud of our accomplishments in 2017. We increased our market leadership position in the extended half-life market with our products ELOCTATE® and ALPROLIX® and grew revenue by 32% year-over-year. We built a robust clinical stage pipeline by advancing internal assets such as BIVV001 into a Phase 1/2a clinical trial, which is progressing with patients being dosed. We acquired True North Therapeutics and have initiated our Phase 3 registrational trials for BIVV009 in cold agglutinin disease,” said John Cox, Chief Executive Officer of Bioverativ.

“As we look toward 2018 and our future, Sanofi brings proven capabilities and a global infrastructure, which we believe will help to rapidly expand access to our medicines globally and further our mission of transforming the lives of people with rare blood disorders. Since its inception, I strongly believed Bioverativ would create meaningful value for shareholders. Our transaction with Sanofi delivers tremendous value for those who have invested in and supported our mission,” continued Mr. Cox.

For earnings history and earnings-related data on Bioverativ Inc. (BIVV) click here.

You May Also Be Interested In

• CarGurus (CARG) Tops Q2 EPS by 5c ; Offers Guidance
• Valhi, Inc. (VHI) Misses Q2 EPS by 18c
• Sprout Social (SPT) Tops Q2 EPS by 10c ; Offers Guidance